PitchBook Analysis: Rebounding Biotech Funding Expected to Drive CDMO Growth in 2026, Focus on Complex Modalities

BioSpace USA

Overview

This article provides an overview of a PitchBook analysis report. According to PitchBook, biotech venture capital funding in the first half of 2026 surpassed $10 billion, driven significantly by Isomorphic Labs’ $2.1 billion Series B round. This funding rebound and the expansion of AI-driven early-stage drug discovery pipelines are projected to increase demand for biopharma services, particularly Contract Development and Manufacturing Organizations (CDMOs). CDMOs are expected to lead this service demand recovery by focusing on complex modalities like cell and gene therapies, antibody-drug conjugates (ADCs), and radiopharmaceuticals.

In Depth

Key Findings

This article provides an overview of an analysis report from PitchBook. According to PitchBook’s analysis, the rebound in biotech venture capital funding during the first half of 2026 is poised to stimulate significant growth within the Contract Development and Manufacturing Organization (CDMO) market. This positive outlook is largely driven by a renewed investor confidence and an expanding pipeline of AI-driven early-stage drug discovery projects, signaling a robust future for biopharma services.

Technical/Clinical Details

The report highlights several key findings:

• Biotech venture capital funding in the first half of 2026 exceeded $10 billion, indicating a broad market recovery. This impressive figure was notably propelled by the $2.1 billion Series B funding secured by Isomorphic Labs, an Alphabet subsidiary, which underscores the substantial investment in AI-driven drug discovery.
• The simultaneous rebound in biotech funding and the expansion of AI-driven early-stage drug discovery pipelines are directly predicted to translate into increased demand for biopharma services, especially CDMOs. As early-stage companies secure more capital, their R&D activities intensify, escalating the need for outsourced manufacturing and development expertise.
• CDMOs are anticipated to spearhead this recovery in service demand by strategically focusing on more complex and specialized modalities. These include cell and gene therapies, antibody-drug conjugates (ADCs), and radiopharmaceuticals. These novel modalities require advanced manufacturing technologies, specialized facilities, and deep regulatory knowledge, thereby expanding opportunities for CDMOs to offer their unique expertise.
• This trend signifies an evolution of the CDMO market from mere contract manufacturers to strategic partners integral to the development and commercialization of innovative therapeutic solutions.

Issuing Company Details

PitchBook is a financial data and software company that provides comprehensive data, research, and technology covering the private markets, including venture capital, private equity, and M&A. Its market trend analyses are an indispensable resource for investors and corporate strategists.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime